Supplemental material
Open access
5,308
Views
31
CrossRef citations to date
0
Altmetric
Report
Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis
Thomas E. Krafta Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
https://orcid.org/0000-0002-5528-3197
Wolfgang F. Richterb Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
, Thomas Emricha Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
https://orcid.org/0000-0003-1179-4697
Alexander Knauppa Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
, Michaela Schustera Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
https://orcid.org/0000-0003-2817-8364
Andreas Wolferta Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
https://orcid.org/0000-0003-3605-0010
Hubert Kettenbergera Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, GermanyCorrespondence[email protected]
show all
Article: 1683432
|
Received 04 Jul 2019, Accepted 18 Oct 2019, Published online: 26 Nov 2019
Related Research Data
Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Source:
Springer Science and Business Media LLC
Biophysical properties of the clinical-stage antibody landscape
Source:
Proceedings of the National Academy of Sciences
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
Source:
Elsevier BV
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Source:
Proceedings of the National Academy of Sciences
Antibody pharmacokinetics and pharmacodynamics.
Source:
Elsevier BV
Therapeutic antibodies: market considerations, disease targets and bioprocessing.
Source:
Elsevier BV
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Source:
Informa UK Limited
Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Source:
Informa UK Limited
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Source:
Informa UK Limited
Target-independent variable region mediated effects on antibody clearance can be FcRn independent
Source:
Informa UK Limited
Genetically Engineered Humanized Mouse Models for Preclinical Antibody Studies
Source:
Springer Science and Business Media LLC
A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
Source:
Elsevier BV
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity
Source:
Elsevier BV
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
Source:
Informa UK Limited
An engineered human IgG1 antibody with longer serum half-life.
Source:
The American Association of Immunologists
Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice
Source:
Informa UK Limited
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Source:
Wiley
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Source:
Informa UK Limited
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.
Source:
Oxford University Press (OUP)
Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
Source:
Elsevier BV
Characterization and screening of IgG binding to the neonatal Fc receptor
Source:
Informa UK Limited
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.